Was jetzt?

Zurück zum Zitat Tan NKW, Tang A, MacAlevey NCYL, Tan BKJ, Oon HH. Risk of Suicide and Psychiatric Disorders Among Isotretinoin Users: A Meta-Analysis. JAMA Dermatol 160(1):54–62, 2024 Tan NKW, Tang A, MacAlevey NCYL, Tan BKJ, Oon HH. Risk of Suicide and Psychiatric Disorders Among Isotretinoin Users: A Meta-Analysis. JAMA Dermatol 160(1):54–62, 2024

Zurück zum Zitat Boesjes CM, van der Gang LF, Bakker DS, Ten CTA, Spekhorst LS, de Graaf M, van Dijk MR, de Bruin-Weller MS (2023) Dupilumab-Associated Lymphoid Reactions in Patients With Atopic Dermatitis. JAMA Dermatol 159(11):1240–1247CrossRefPubMed Boesjes CM, van der Gang LF, Bakker DS, Ten CTA, Spekhorst LS, de Graaf M, van Dijk MR, de Bruin-Weller MS (2023) Dupilumab-Associated Lymphoid Reactions in Patients With Atopic Dermatitis. JAMA Dermatol 159(11):1240–1247CrossRefPubMed

Zurück zum Zitat Maurer M, Ensina LF, Gimenez-Arnau AM, Sussman G, Hide M, Saini S, Grattan C, Fomina D, Rigopoulos D, Berard F, Canonica GW, Rockmann H, Irani C, Szepietowski JC, Leflein J, Bernstein JA, Peter JG, Kulthanan K, Godse K, Ardusso L, Ukhanova O, Staubach P, Sinclair R, Gogate S, Thomsen SF, Tanus T, Ye YM, Burciu A, Barve A, Modi D, Scosyrev E, Hua E, Letzelter K, Varanasi V, Patekar M, Severin T, PEARL‑1 and PEARL‑2 trial investigators. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria (2024) results of two phase 3 randomised controlled trials. Lancet 403(10422):147–159CrossRefPubMed Maurer M, Ensina LF, Gimenez-Arnau AM, Sussman G, Hide M, Saini S, Grattan C, Fomina D, Rigopoulos D, Berard F, Canonica GW, Rockmann H, Irani C, Szepietowski JC, Leflein J, Bernstein JA, Peter JG, Kulthanan K, Godse K, Ardusso L, Ukhanova O, Staubach P, Sinclair R, Gogate S, Thomsen SF, Tanus T, Ye YM, Burciu A, Barve A, Modi D, Scosyrev E, Hua E, Letzelter K, Varanasi V, Patekar M, Severin T, PEARL‑1 and PEARL‑2 trial investigators. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria (2024) results of two phase 3 randomised controlled trials. Lancet 403(10422):147–159CrossRefPubMed